Are flashcards effective for the MPJE exam?

Yes. Flashcards use active recall — retrieving an answer from memory — which research shows is one of the most effective study methods, especially in short, spaced sessions. They're ideal for the MPJE's heavy law facts: DEA forms, schedules, refill limits, time frames, and recordkeeping rules.

What topics do the MPJE flashcards cover?

The federal core common to every state's MPJE: controlled substances (DEA schedules, forms, refill and transfer rules, CMEA), pharmacist practice (prescription elements, OBRA-90 counseling and DUR, substitution), licensure and personnel, and pharmacy operations (ordering, inventory, HIPAA, packaging, USP standards).

How should I study with these MPJE flashcards?

Lead with controlled-substance law — DEA schedules, refill limits, and recordkeeping — since it is the most-tested federal content. Mix the modes: flip to learn, type to test recall, match for speed, and quiz to check yourself. Pair them with your state's pharmacy law for the state-specific questions.

Are the MPJE flashcards free?

Yes — 100% free, all four study modes, no paywall and no sign-up.

Do these flashcards match the current MPJE exam?

Yes. The cards are built around NABP's current MPJE Competency Statements and verified against federal primary sources (the DEA, FDA, HHS, and Title 21 of the Code of Federal Regulations). Always confirm your state's pharmacy law for the state-specific portion.

The official order form required to purchase or transfer Schedule I and II controlled substances (or the electronic CSOS equivalent).

The application a pharmacy uses to obtain a new DEA registration to dispense controlled substances.

The form used to document the destruction/disposal of unwanted controlled substances.

The form used to report the theft or significant loss of controlled substances to the DEA.

Highest abuse potential, no currently accepted U.S. medical use (e.g., heroin, LSD). Not dispensed at pharmacies.

High abuse potential with accepted medical use; severe dependence risk (e.g., oxycodone, fentanyl, amphetamine). No refills.

Abuse potential less than CI–CII; moderate-to-low physical dependence (e.g., buprenorphine, ketamine, certain codeine combos).

Low abuse potential relative to CIII (e.g., benzodiazepines, tramadol, zolpidem).

Lowest abuse potential; preparations with limited quantities of certain narcotics (e.g., codeine cough syrups, pregabalin).

Schedule II refill rule

Schedule II prescriptions may NOT be refilled. A new prescription is required each time.

Schedule III–V refill limit

May be refilled up to 5 times within 6 months of the date written; after that a new prescription is needed.

Schedule II written-prescription rule

Generally require a written (or compliant electronic) prescription; oral orders allowed only in a genuine emergency.

Emergency Schedule II oral order

Permitted in a bona fide emergency, limited to the amount needed for the emergency period; prescriber must deliver a written prescription within 7 days.

Schedule II partial fill (federal)

A partial fill is allowed; the remainder may be supplied within 72 hours, otherwise the balance is void and the prescriber must be notified.

Schedule III–V partial fill

Partial fills are allowed as long as each is recorded like a refill and the total dispensed does not exceed the amount prescribed within 6 months.

Controlled-substance prescription transfer (CIII–V)

May be transferred for refill purposes ONE time only; if pharmacies share a real-time online database, up to the maximum number of refills is allowed.

CII prescriptions cannot be transferred for refilling (CII has no refills). Under a 2023 DEA rule, an ELECTRONIC CII–CV prescription may be transferred once, pharmacist-to-pharmacist, for the INITIAL fill.

Controlled Substances Act (CSA)

The 1970 federal law (Title 21) that classifies drugs into Schedules I–V and governs their manufacture, distribution, and dispensing through the DEA.

The Drug Enforcement Administration — the federal agency that registers handlers and enforces the Controlled Substances Act.

DEA registration renewal

A pharmacy's DEA registration must be renewed every 3 years.

Valid DEA number check

First letter shows registrant type; second letter is the registrant's last-name initial. Checksum: add the 1st, 3rd, and 5th digits; double the sum of the 2nd, 4th, and 6th; the last digit of the total equals the 7th (check) digit.

Legitimate medical purpose

A controlled-substance prescription is valid only if issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice (21 CFR 1306.04).

Corresponding responsibility

The dispensing pharmacist shares legal responsibility with the prescriber for ensuring a controlled-substance prescription is legitimate; knowingly filling an invalid one is a violation.

Red flags (controlled substances)

Warning signs of diversion — e.g., cash payment for high-dose opioids, long distances traveled, identical prescriptions for many patients, early refills, dangerous combinations.

Power of attorney (DEA Form 222)

A registrant may grant a power of attorney authorizing an individual to sign DEA Form 222 / CSOS orders on the registrant's behalf; it is kept on file at the registered location.

Controlled Substance Ordering System — DEA's program for placing electronic Schedule I/II orders using a DEA-issued digital certificate, replacing the paper Form 222.

DEA Form 222 completion limit (paper)

Must be filled out and submitted to the supplier within 60 days of the order date.

Theft/loss reporting timing

A pharmacy must notify the DEA in writing within 1 business day of discovering a theft or significant loss, then complete DEA Form 106.

A complete inventory of all controlled substances must be taken at least every 2 years.

A newly registered pharmacy must take an inventory of all controlled substances on hand on the date it first engages in handling them.

Schedule II inventory count

Schedule II substances must be counted EXACTLY; Schedule III–V may be estimated unless the container holds more than 1,000 dosage units.

Controlled-substance record retention (federal)

Controlled-substance records must be kept for at least 2 years and be readily retrievable.

Records can be separated from other documents or marked so that controlled-substance information is easily identifiable and produced for inspection.

Schedule II recordkeeping

Schedule II records must be maintained SEPARATELY from all other records.

Schedule III–V recordkeeping

May be kept separately OR in a readily retrievable form within the other prescription files.

Federal transfer warning label

Schedule II–IV labels must bear: “Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed.”

Combat Methamphetamine Epidemic Act (CMEA)

Federal law limiting OTC sales of pseudoephedrine, ephedrine, and phenylpropanolamine; requires behind-the-counter storage, a logbook, and ID verification.

Pseudoephedrine daily limit

A customer may purchase no more than 3.6 grams of pseudoephedrine base per day.

Pseudoephedrine 30-day limit

No more than 9 grams may be purchased within a 30-day period (federal CMEA limit).

Pseudoephedrine logbook retention

The CMEA sales logbook must be kept for at least 2 years.

Practitioner self-prescribing (controlled)

Prescribing controlled substances for oneself or for office stock generally lacks a legitimate prescriber–patient relationship and is not a valid prescription.

Telemedicine controlled prescribing

A controlled-substance prescription via telemedicine requires a genuine evaluation and a practitioner–patient relationship consistent with federal Ryan Haight Act requirements.

Schedule II prescription expiration (federal)

Federal law sets no time limit for filling an unfilled CII prescription, but it must still reflect a legitimate medical need (many states do impose a limit).

Disposal / reverse distributor

Unwanted controlled substances are sent to a DEA-registered reverse distributor (with Form 222 for CII) and documented on DEA Form 41.

Manufacturers, distributors, dispensers (pharmacies/practitioners), importers/exporters, researchers, and analytical labs each register separately by activity.

Your FREE MPJE Flashcards 2026 – 200+ Cards

Realistic, MPJE exam-style flashcards on federal pharmacy law — flip, match, type, and quiz yourself.

Master cards to boost your scoreMaster cards to raise your exam readiness score

How well do you know them?

MPJE Flashcards

DEA Form 222: The official order form required to purchase or transfer Schedule I and II controlled substances (or the electronic CSOS equivalent).
DEA Form 224: The application a pharmacy uses to obtain a new DEA registration to dispense controlled substances.
DEA Form 41: The form used to document the destruction/disposal of unwanted controlled substances.
DEA Form 106: The form used to report the theft or significant loss of controlled substances to the DEA.
Schedule I: Highest abuse potential, no currently accepted U.S. medical use (e.g., heroin, LSD). Not dispensed at pharmacies.
Schedule II: High abuse potential with accepted medical use; severe dependence risk (e.g., oxycodone, fentanyl, amphetamine). No refills.
Schedule III: Abuse potential less than CI–CII; moderate-to-low physical dependence (e.g., buprenorphine, ketamine, certain codeine combos).
Schedule IV: Low abuse potential relative to CIII (e.g., benzodiazepines, tramadol, zolpidem).
Schedule V: Lowest abuse potential; preparations with limited quantities of certain narcotics (e.g., codeine cough syrups, pregabalin).
Schedule II refill rule: Schedule II prescriptions may NOT be refilled. A new prescription is required each time.
Schedule III–V refill limit: May be refilled up to 5 times within 6 months of the date written; after that a new prescription is needed.
Schedule II written-prescription rule: Generally require a written (or compliant electronic) prescription; oral orders allowed only in a genuine emergency.
Emergency Schedule II oral order: Permitted in a bona fide emergency, limited to the amount needed for the emergency period; prescriber must deliver a written prescription within 7 days.
Schedule II partial fill (federal): A partial fill is allowed; the remainder may be supplied within 72 hours, otherwise the balance is void and the prescriber must be notified.
Schedule III–V partial fill: Partial fills are allowed as long as each is recorded like a refill and the total dispensed does not exceed the amount prescribed within 6 months.
Controlled-substance prescription transfer (CIII–V): May be transferred for refill purposes ONE time only; if pharmacies share a real-time online database, up to the maximum number of refills is allowed.
Schedule II transfer: CII prescriptions cannot be transferred for refilling (CII has no refills). Under a 2023 DEA rule, an ELECTRONIC CII–CV prescription may be transferred once, pharmacist-to-pharmacist, for the INITIAL fill.
Controlled Substances Act (CSA): The 1970 federal law (Title 21) that classifies drugs into Schedules I–V and governs their manufacture, distribution, and dispensing through the DEA.
DEA: The Drug Enforcement Administration — the federal agency that registers handlers and enforces the Controlled Substances Act.
DEA registration renewal: A pharmacy's DEA registration must be renewed every 3 years.
Valid DEA number check: First letter shows registrant type; second letter is the registrant's last-name initial. Checksum: add the 1st, 3rd, and 5th digits; double the sum of the 2nd, 4th, and 6th; the last digit of the total equals the 7th (check) digit.
Legitimate medical purpose: A controlled-substance prescription is valid only if issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice (21 CFR 1306.04).
Corresponding responsibility: The dispensing pharmacist shares legal responsibility with the prescriber for ensuring a controlled-substance prescription is legitimate; knowingly filling an invalid one is a violation.
Red flags (controlled substances): Warning signs of diversion — e.g., cash payment for high-dose opioids, long distances traveled, identical prescriptions for many patients, early refills, dangerous combinations.
Power of attorney (DEA Form 222): A registrant may grant a power of attorney authorizing an individual to sign DEA Form 222 / CSOS orders on the registrant's behalf; it is kept on file at the registered location.
CSOS: Controlled Substance Ordering System — DEA's program for placing electronic Schedule I/II orders using a DEA-issued digital certificate, replacing the paper Form 222.
DEA Form 222 completion limit (paper): Must be filled out and submitted to the supplier within 60 days of the order date.
Theft/loss reporting timing: A pharmacy must notify the DEA in writing within 1 business day of discovering a theft or significant loss, then complete DEA Form 106.
Biennial inventory: A complete inventory of all controlled substances must be taken at least every 2 years.
Initial inventory: A newly registered pharmacy must take an inventory of all controlled substances on hand on the date it first engages in handling them.
Schedule II inventory count: Schedule II substances must be counted EXACTLY; Schedule III–V may be estimated unless the container holds more than 1,000 dosage units.
Controlled-substance record retention (federal): Controlled-substance records must be kept for at least 2 years and be readily retrievable.
Readily retrievable: Records can be separated from other documents or marked so that controlled-substance information is easily identifiable and produced for inspection.
Schedule II recordkeeping: Schedule II records must be maintained SEPARATELY from all other records.
Schedule III–V recordkeeping: May be kept separately OR in a readily retrievable form within the other prescription files.
Federal transfer warning label: Schedule II–IV labels must bear: “Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed.”
Combat Methamphetamine Epidemic Act (CMEA): Federal law limiting OTC sales of pseudoephedrine, ephedrine, and phenylpropanolamine; requires behind-the-counter storage, a logbook, and ID verification.
Pseudoephedrine daily limit: A customer may purchase no more than 3.6 grams of pseudoephedrine base per day.
Pseudoephedrine 30-day limit: No more than 9 grams may be purchased within a 30-day period (federal CMEA limit).
Pseudoephedrine logbook retention: The CMEA sales logbook must be kept for at least 2 years.
Practitioner self-prescribing (controlled): Prescribing controlled substances for oneself or for office stock generally lacks a legitimate prescriber–patient relationship and is not a valid prescription.
Telemedicine controlled prescribing: A controlled-substance prescription via telemedicine requires a genuine evaluation and a practitioner–patient relationship consistent with federal Ryan Haight Act requirements.
Schedule II prescription expiration (federal): Federal law sets no time limit for filling an unfilled CII prescription, but it must still reflect a legitimate medical need (many states do impose a limit).
Disposal / reverse distributor: Unwanted controlled substances are sent to a DEA-registered reverse distributor (with Form 222 for CII) and documented on DEA Form 41.
DEA registrant types: Manufacturers, distributors, dispensers (pharmacies/practitioners), importers/exporters, researchers, and analytical labs each register separately by activity.
Schedule II faxed prescription (exceptions): A faxed CII may serve as the original for long-term-care, hospice, or home-infusion patients (and to confirm an emergency oral order).
Multiple Schedule II prescriptions: A practitioner may issue multiple CII prescriptions on the same day for up to a 90-day supply, with instructions on the earliest fill date for each.
Suspicious order monitoring: Distributors must design systems to detect and report suspicious controlled-substance orders to the DEA.
Required prescription elements: Patient name and address, date, drug name/strength/quantity, directions for use, prescriber name/address (and signature), and prescriber DEA number for controlled drugs.
OBRA-90: The Omnibus Budget Reconciliation Act of 1990 — requires offer to counsel and prospective drug-use review (DUR) for Medicaid patients; adopted broadly by states for all patients.
Offer to counsel: Under OBRA-90, the pharmacist (or designee) must OFFER to counsel the patient; the patient may decline, but the offer is required.
Prospective drug utilization review (ProDUR): Screening a prescription before dispensing for therapeutic duplication, interactions, contraindications, incorrect dose/duration, and abuse/misuse.
Patient counseling content: Drug name, intended use, route/dose/duration, special directions, common side effects and how to avoid them, storage, refills, and what to do if a dose is missed.
Generic substitution: A pharmacist may substitute a therapeutically equivalent generic unless the prescriber indicates “dispense as written” / “brand medically necessary” or the patient refuses.
Orange Book: FDA's “Approved Drug Products with Therapeutic Equivalence Evaluations” — used to determine if a generic is therapeutically equivalent (A-rated) to the brand.
Dispense as written (DAW): A prescriber instruction directing that the brand-name product be dispensed without generic substitution.
Prescriptive authority by prescriber: Physicians (MD/DO), dentists, podiatrists, veterinarians, optometrists, and mid-level practitioners (NP, PA) prescribe within the scope of their license and DEA authority.
Podiatrist prescribing scope: A podiatrist may prescribe only for conditions of the foot and ankle within their licensed scope.
Mid-level practitioner DEA: Nurse practitioners and physician assistants may prescribe controlled substances only as allowed by state law and with their own DEA registration.
Suspended prescriber: A prescription written while the prescriber's license or DEA registration is suspended/revoked is not valid and must not be filled.
Fax prescription (non-controlled): A non-controlled prescription may be transmitted by fax and serve as the original.
Electronic prescribing of controlled substances (EPCS): Allowed under DEA rules when the system meets identity-proofing, two-factor authentication, and audit requirements.
Verbal/oral prescription: Non-controlled and CIII–V prescriptions may be taken orally; CII generally may not except in a documented emergency.
Clarifying an ambiguous order: When a prescription is unclear, incomplete, or potentially in error, the pharmacist must contact the prescriber to clarify before dispensing.
Therapeutic interchange vs substitution: Substitution swaps a generic for the same drug; therapeutic interchange swaps a different drug in the same class, usually requiring a protocol or prescriber approval.
Refill authorization: Refills require prescriber authorization; without remaining authorized refills the pharmacist must obtain a new authorization.
Emergency refill (state): Many states allow a limited emergency supply of a maintenance non-controlled drug when the prescriber cannot be reached; amount and conditions are set by state law.
Drug Utilization Review (DUR) outcome: If ProDUR detects a problem, the pharmacist exercises professional judgment — contacting the prescriber and/or counseling — before dispensing.
Patient profile / medication record: A record of the patient's medications, allergies, and conditions that supports DUR and counseling (required under OBRA-90 for Medicaid patients).
Tamper-resistant prescription pad: Medicaid outpatient prescriptions must be on tamper-resistant pads (or e-prescribed) to be reimbursed.
Quantity vs days supply: Quantity is the amount dispensed; days supply is how long it lasts per the directions — both are checked against the prescription.
Pharmacist scope (vaccines/test-and-treat): Pharmacists may immunize and, in many states, test-and-treat under protocols or collaborative practice agreements set by state law.
Collaborative practice agreement (CPA): A written agreement letting a pharmacist manage drug therapy (adjust, initiate, monitor) under a prescriber's authorization, per state law.
Refusal to fill (conscientious/professional): A pharmacist may decline to fill a prescription the pharmacist believes is invalid, forged, or not for a legitimate medical purpose, and must document the basis.
Right of the patient to decline counseling: OBRA-90 requires the offer; the patient may refuse counseling, which is then documented.
Forged prescription handling: Suspected forgeries should not be filled; verify with the prescriber and follow state/federal reporting requirements.
Schedule of the prescriber's DEA: A prescriber's DEA registration authorizes specific schedules; the pharmacist confirms the prescriber is authorized for the controlled drug ordered.
Patient identification for controlled dispensing: Many states require ID for controlled-substance pickup; the pharmacist verifies the patient/agent per state rules.
Beyond-use date (dispensed Rx): The date beyond which a dispensed prescription should not be used, assigned per USP guidance and the product's stability.
Drug recall classes (FDA): Class I = reasonable probability of serious harm/death; Class II = temporary or reversible harm; Class III = unlikely to cause harm.
Pharmacist's role in a recall: Identify affected stock, quarantine it, follow the manufacturer/FDA instructions, and notify patients/prescribers as directed.
MPJE: The Multistate Pharmacy Jurisprudence Examination — NABP's computer-adaptive law exam (120 items: 90 scored + 30 pretest, 3 hours) combining federal pharmacy law with a specific state's law.
MPJE competency areas: Per NABP's current Competency Statements: Area 1 Pharmacy Practice (~83%), Area 2 Licensure/Registration/Certification & Operational Requirements (15%), and Area 3 General Regulatory Processes (2%).
MPJE passing score: A scaled score of 75 on a 0–100 scale; since 2021 results are reported pass/fail. Because it is computer-adaptive, the cut is not a simple percent-correct.
UMPJE: The Uniform MPJE — NABP's newer law exam (launched 2026) testing uniform state-law principles plus federal law using 3-option single-answer questions; replacing the MPJE in adopting jurisdictions.
NABP: The National Association of Boards of Pharmacy — develops and administers the NAPLEX and MPJE/UMPJE and supports state boards of pharmacy.
Board of pharmacy: The state agency that licenses pharmacists/pharmacies, sets and enforces practice rules, and disciplines licensees within that jurisdiction.
NAPLEX vs MPJE: NAPLEX tests pharmacy practice/clinical competence; the MPJE tests pharmacy law and jurisprudence for a specific state.
State-specific MPJE: Each state's MPJE blends FEDERAL pharmacy law with that state's own pharmacy statutes and board regulations; a separate MPJE is required for each state, and you answer per the prevailing law of that state.
States requiring the MPJE: 45 boards of pharmacy require an NABP law exam (MPJE or UMPJE). Arkansas, California, Nevada, and Puerto Rico give their own jurisprudence exams; a few jurisdictions require no law exam.
MPJE/UMPJE fee: The MPJE application fee is $100 per jurisdiction (plus state board fees). The UMPJE costs $450 total ($100 application + $350 exam), with $105 per additional jurisdiction.
MPJE retake wait: A candidate must wait at least 30 days between attempts and reapply each time; the number of attempts allowed is set by the state board.
Licensure by examination: Initial licensure path: graduate from an accredited program, pass the NAPLEX and the state's MPJE, and complete required intern hours.
Licensure reciprocity / transfer: Transferring a license to another state via NABP's licensure transfer process; the candidate must still pass that state's MPJE.
Continuing education (CE): Ongoing education required to renew a license and maintain competence; measured in CE units/hours set by the state.
Continuing education unit (CEU): A standardized measure of CE; 1 CEU = 10 contact hours (so 0.1 CEU = 1 contact hour).
License renewal: Pharmacist licenses are renewed periodically (commonly every 1–2 years) with required CE; lapse requires reinstatement per state rules.
Pharmacy intern: A student or graduate registered with the board to gain supervised practice experience toward licensure.
Pharmacist-in-charge (PIC): The pharmacist legally responsible for a pharmacy's compliance with laws and regulations, including recordkeeping and operations.
Pharmacy technician: Supportive personnel who assist the pharmacist with dispensing tasks under supervision; registration/certification and duties are set by state law.
Technician-to-pharmacist ratio: The maximum number of technicians a pharmacist may supervise, set by state law (varies by state).
Final verification: Most states require a pharmacist to perform the final check of a dispensed prescription (some allow tech-check-tech under board-approved programs).
Pharmacy permit/registration: A pharmacy must hold a current state permit/registration (and DEA registration for controlled substances) to operate.
Out-of-state / nonresident pharmacy license: A pharmacy mailing prescriptions into a state generally must hold that state's nonresident pharmacy license.
Change of pharmacy ownership/location: Requires notifying the board (and modifying the DEA registration) per state and federal rules before the change takes effect.
Disciplinary actions: A board may suspend, revoke, fine, place on probation, or reprimand a licensee for violations such as fraud, diversion, or impairment.
Grounds for discipline: Common grounds include unprofessional conduct, drug diversion, fraud, substance impairment, gross negligence, and violation of pharmacy law.
Mandatory reporting: Licensees must report certain events (e.g., disciplinary action in another state, certain crimes) to the board as required by state law.
Impaired-pharmacist program: A confidential recovery/monitoring program some boards offer in lieu of or alongside discipline for substance-use disorders.
Inspection authority: Boards and the DEA may inspect a pharmacy's premises and records to verify compliance; controlled-substance records must be readily retrievable.
Pharmacy closing requirements: On closure, controlled stock is transferred or disposed of with proper documentation, and records and the DEA registration are handled per regulation.
CE for license reactivation: A lapsed license is reactivated by meeting the board's requirements, which often include completing back/required CE and paying fees.
Pharmacist supervision requirement: A pharmacy may dispense only under the supervision of a licensed pharmacist who is on duty/responsible.
Registration vs license: A license authorizes a person to practice; a registration (e.g., technician, intern, DEA) authorizes a specific activity or status.
Poison Prevention Packaging Act (PPPA): Requires child-resistant containers for most oral prescription drugs unless the prescriber or patient requests otherwise (a per-prescription or blanket patient waiver).
Child-resistant packaging exemptions: Certain drugs (e.g., sublingual nitroglycerin, some inhalers, oral contraceptives in their dispensing packages) are exempt from child-resistant packaging.
Patient waiver of safety cap: A patient may request non-child-resistant packaging (a blanket waiver is allowed); a prescriber may waive only on a single-prescription basis.
HIPAA Privacy Rule: Protects individually identifiable health information (PHI); permits use/disclosure for treatment, payment, and health-care operations and limits other uses to the minimum necessary.
Protected health information (PHI): Individually identifiable health information held or transmitted by a covered entity, protected under HIPAA.
Minimum necessary standard: HIPAA principle of using or disclosing only the least PHI needed to accomplish the purpose.
Notice of Privacy Practices (NPP): A document a pharmacy must provide describing how it uses and discloses PHI and the patient's rights.
Prescription label requirements: Typically: pharmacy name/address, serial/Rx number, date, prescriber name, patient name, directions, drug name/strength, and required cautionary statements.
Manufacturer/repackaged label requirements (FDCA): Drug labeling must include adequate directions for use, ingredients, lot number, expiration date, and required warnings under the FDCA.
Federal record retention (non-controlled): Federal law focuses on 2 years for controlled records; non-controlled record retention is largely set by state law (commonly 2–7 years).
Prescription file separation (federal): CII filed separately; CIII–V either separate or readily retrievable; non-controlled in the general file.
USP <795>: Standards for non-sterile compounding (e.g., creams, capsules, oral liquids), including beyond-use dating and documentation.
USP <797>: Standards for sterile compounding to prevent contamination — air quality, garbing, environmental monitoring, and beyond-use dating.
USP <800>: Standards for handling hazardous drugs to protect personnel and the environment, including storage, containment, and PPE.
Hazardous drug storage: Per USP <800>, hazardous drugs are stored separately, in a negative-pressure, externally vented area (refrigerated HDs in a dedicated negative-pressure refrigerator).
Compounding vs manufacturing: Compounding prepares a drug for a specific patient based on a prescriber relationship; manufacturing produces drugs for general distribution and requires FDA registration.
503A vs 503B: 503A = traditional patient-specific compounding pharmacies; 503B = outsourcing facilities that compound in bulk under FDA cGMP oversight.
Central fill pharmacy: A pharmacy that fills/refills prescriptions on behalf of another pharmacy under a contractual or common-ownership arrangement, with records linking both.
Drug Supply Chain Security Act (DSCSA): Establishes an electronic, interoperable system to trace prescription drugs through the supply chain to protect against counterfeit/diverted products.
Transaction history / verification (DSCSA): Trading partners must capture product tracing information and verify suspect/illegitimate product, quarantining and investigating as required.
Federal Food, Drug, and Cosmetic Act (FDCA): The foundational FDA law governing drug safety, efficacy, labeling, adulteration, and misbranding.
Adulteration: A drug is adulterated if it is contaminated, prepared/held under unsanitary conditions, or fails to meet purity/strength standards.
Misbranding: A drug is misbranded if its labeling is false or misleading, lacks required information, or lacks adequate directions for use.
Legend drug (Rx-only): A prescription drug bearing “Rx only”; under the FDCA it may be dispensed only on a valid prescription.
OTC drug: A drug that meets FDA monograph standards and may be sold without a prescription with appropriate Drug Facts labeling.
Behind-the-counter (BTC): Products kept behind the counter and sold without a prescription but with pharmacist involvement or record (e.g., pseudoephedrine under CMEA).
Expired-drug control: Pharmacies must remove expired/deteriorated drugs from active stock; controlled stock for destruction is documented (Form 41).
Recall recordkeeping: Document recall notices, quarantined stock, and actions taken so the response is traceable on inspection.
PDMP: Prescription Drug Monitoring Program — a state database tracking dispensed controlled substances; many states require querying it before dispensing certain drugs.
PDMP reporting: Pharmacies report dispensed controlled-substance data to the state PDMP within the timeframe set by state law.
Security of controlled stock: Controlled substances must be stored in a securely locked, substantially constructed cabinet OR dispersed throughout non-controlled stock to deter theft.
Wholesaler verification: A pharmacy may only purchase controlled substances from a DEA-registered distributor, using Form 222/CSOS for Schedule II.
Returns of dispensed drugs: Dispensed prescription drugs generally cannot be returned to stock once they leave the pharmacy, except in limited settings (e.g., some long-term-care unit-dose).
Prescription serial/number system: Each filled prescription receives a unique identifying number, recorded on the label and in the pharmacy record for traceability.
Computer/manual recordkeeping requirement: Pharmacies must maintain accurate records (electronic or paper) of dispensing and inventory that are readily retrievable for inspection.
Hazardous-drug spill kit: USP <800> requires accessible spill kits and trained personnel to contain and clean hazardous-drug spills.
Temperature monitoring: Refrigerated and frozen drugs (incl. many vaccines) must be stored within labeled ranges with documented temperature monitoring.
Repackaging/relabeling: When repackaging into a different container, the pharmacy must preserve required labeling, lot number, and a beyond-use date per USP.
Schedule II oral emergency quantity: Limited to the amount adequate to treat the patient during the emergency period only.
Who may sign DEA Form 222: The person who signed the most recent DEA registration application, or a person holding a valid power of attorney from that registrant.
Lost/damaged Form 222: If a Form 222 is lost or unusable, the executed copies are kept and the error is documented; CSOS avoids paper-form errors entirely.
Schedule II prescription quantity limit (federal): Federal law sets no maximum quantity for a CII prescription, but it must reflect legitimate medical need; states may impose day-supply limits.
Refill record (controlled): Each refill of a CIII–V drug must be documented (date, quantity, dispenser) on the back of the prescription or in an equivalent electronic record.
Central fill of controlled substances: Permitted between pharmacies under DEA rules, with records identifying which pharmacy did the filling and which received the drug.
Schedule designation example — fentanyl: Fentanyl is a Schedule II controlled substance.
Schedule designation example — alprazolam: Alprazolam (Xanax) is a Schedule IV controlled substance.
Schedule designation example — buprenorphine: Buprenorphine products are Schedule III controlled substances.
Schedule designation example — codeine cough syrup: Limited-quantity codeine cough preparations are Schedule V.
Triplicate / multiple-copy state forms: Some states require special serialized prescription forms for controlled substances in addition to federal rules.
Mailing controlled substances: Controlled substances may be mailed under USPS rules in plain packaging with no markings indicating the contents.
DEA inspection (Form 82 / ADIE): Inspectors may request an Administrative Inspection Warrant; a registrant can also consent to inspection of records and premises.
Schedule II label — no refills: A CII prescription label must not indicate refills; none are permitted.
Brand medically necessary: A handwritten or e-prescribed indication by the prescriber that overrides generic substitution for a Medicaid prescription.
Counseling for mail-order/refills: OBRA-90's offer-to-counsel applies to new prescriptions; many states extend counseling rights to refills and mail order via written information.
Patient package insert (PPI): Required for certain drugs (e.g., oral contraceptives, estrogens) to be dispensed to the patient with each fill.
Medication guide (MedGuide): FDA-required patient information for certain drugs with serious risks; must be provided when the drug is dispensed.
REMS: Risk Evaluation and Mitigation Strategy — an FDA-required safety program for certain high-risk drugs (e.g., clozapine, isotretinoin) that may include pharmacy certification.
Isotretinoin / iPLEDGE: A REMS program requiring registration and pregnancy-test verification before dispensing isotretinoin.
Veterinary prescription: A veterinarian may prescribe within the scope of veterinary practice; the pharmacist verifies authority and labels accordingly.
Optometrist prescribing: Optometrists may prescribe drugs for eye conditions within their state-defined scope.
Dentist prescribing: Dentists may prescribe drugs related to dental care within their scope and DEA authority.
Transfer of non-controlled refills: Non-controlled prescription refills may generally be transferred between pharmacies without the one-time limit that applies to controlled drugs.
Patient's right to refuse generic: A patient may insist on the brand even when substitution is otherwise allowed; cost may then fall to the patient.
Prescriber verification of new prescriber: When a prescriber is unfamiliar, the pharmacist confirms licensure and DEA authority before filling controlled prescriptions.
Adequate directions for use: A legend drug is exempt from the FDCA's 'adequate directions for layperson' requirement because it is dispensed on a prescription with professional directions.
Out-of-state prescription: A pharmacist may fill a valid out-of-state prescription if it meets that prescriber's authority and the dispensing state's rules (controlled-drug rules still apply).
Pharmacy intern hours: States require a set number of supervised internship/experiential hours for licensure (commonly ~1,500 hours).
Foreign pharmacy graduate (FPGEC): Foreign graduates typically must obtain FPGEC certification (incl. FPGEE and English proficiency) before licensure eligibility.
Score transfer (NABP): A NAPLEX/UMPJE score may be transferred to additional jurisdictions through NABP for a per-jurisdiction fee; the state's law exam may still be required.
Continuing-education topics: Some CE hours may be required in specific subjects (e.g., law, patient safety, opioids) as set by the state board.
Pharmacist license display: A current license/registration generally must be displayed or available at the practice site.
Tech-check-tech (TCT): Some boards permit a trained technician to verify another technician's product filling under board-approved programs, usually for unit-dose/inpatient settings.
Authentication of authority (PIC): The pharmacist-in-charge ensures the pharmacy's policies, recordkeeping, and personnel comply with applicable law.
Change-of-PIC notification: A change in the pharmacist-in-charge usually must be reported to the board within a set time and may require a closing inventory.
Reinstatement after lapse: A lapsed license is reinstated by application, payment of fees, and meeting CE/competency requirements set by the board.
NDC number: National Drug Code — a unique 3-segment identifier (labeler–product–package) the FDA assigns to a drug product.
Tamper-resistant packaging (OTC): Required for most OTC products so consumers can detect if a package has been opened or altered.
Expiration date vs beyond-use date: An expiration date is set by the manufacturer for the original container; a beyond-use date is assigned by the pharmacy for a repackaged or compounded product.
Drug shortage management: Pharmacies may use FDA shortage resources and, where lawful, compounding to address documented shortages.
Investigational drugs: Investigational drugs are handled under FDA IND rules and institutional protocols, with controlled distribution and recordkeeping.
Prescription drug advertising: The FDA (not the pharmacy) regulates prescription drug advertising for accuracy and fair balance under the FDCA.
Repackaging into compliance packaging: Adherence (blister/bingo) packaging must retain required labeling and an appropriate beyond-use date.
Pharmacy security after hours: Controlled substances must remain secured (locked storage or dispersal) and the prescription department secured when no pharmacist is on duty.
Schedule III–V estimate threshold: During inventory, CIII–V may be estimated unless a container holds more than 1,000 dosage units, which must be counted exactly.
Records readily retrievable for inspection: All required pharmacy records must be produced for board or DEA inspection during normal business hours.
Hazardous-drug receiving (USP 800): Hazardous drugs are received and unpacked in a neutral/negative-pressure area away from sterile compounding and using appropriate PPE.
Sterile compounding garbing order (USP 797): Garb is donned dirtiest-to-cleanest (shoe covers, head/facial hair, mask, then hand hygiene and gown, then sterile gloves in the buffer area).
Patient record confidentiality: Pharmacy records are confidential under HIPAA and state law; disclosure is limited to permitted purposes and the minimum necessary.
Disposal of non-controlled drugs: Non-controlled drug disposal follows EPA/state environmental rules; many drugs cannot be flushed and use take-back or hazardous-waste streams.

To find us again, just search “Career Employer MPJE”

By Career EmployerUpdated Jun 19, 2026

200+ free MPJE flashcards — 4 ways to study

MPJE Flashcard of the DayNew daily

The classic card. Do you know this one?

Click Study Flashcards above to open the flashcard hub — hundreds of MPJE cards you can flip, match, type, or quiz yourself on. Every card covers the federal pharmacy law the exam tests, built around NABP’s current competency areas.^[2] Pair them with our free practice test and study guide, and study your state’s law for the state-specific portion.

MPJE Flashcard Study Modes

Most flashcard sites give you one thing: a card to flip. Ours has four modes so you can both learn the material and prove you know it — the difference between recognizing an answer and recalling it under exam pressure.

Flip (Study) — the classic card. Flip term ↔ definition, shuffle the deck, and mark each card “Got it” or “Still learning.”
Match (Game) — a timed game: pair each term to its definition as fast as you can. Great for cementing DEA forms, schedules, and time frames.
Type (Recall) — read the definition and type the term. Typing forces true active recall instead of passive recognition.
Quiz (Test) — multiple-choice questions generated from the cards, so you self-test exactly like exam day.

Free MPJE flashcards from Career Employer — active recall for the NABP pharmacy jurisprudence exam

Why Flashcards Work for the MPJE

Flashcards aren’t busywork — they’re built on active recall: pulling an answer out of memory strengthens it far more than re-reading notes. Pair that with spacing — short sessions across several days rather than one cram — and you retain more in less time.

The MPJE is dense with precise legal facts — DEA forms and schedules, refill and transfer rules, time frames, inventory and recordkeeping requirements, and pseudoephedrine limits.^[3] Spaced flashcards are the most efficient way to keep it all fresh. Used alongside our practice test and study guide, they turn review time into measurable progress.

MPJE Flashcards by Topic

The cards are organized by the federal law the exam tests. Drill controlled-substance law first — it is the strictest and most-tested:^[2]

MPJE flashcards by topic
Topic	What it covers
Controlled Substances & Federal Law	DEA schedules & forms, refills, transfers, partial fills, CMEA
Pharmacist Practice & Dispensing	Prescription elements, prescriptive authority, OBRA-90, substitution
Licensure, Registration & Personnel	DEA/state registration, licensure & CE, technicians, supervision
Pharmacy Operations & Compliance	Ordering, inventory, recordkeeping, HIPAA, packaging, USP standards

How to Get the Most Out of These Flashcards

Lead with controlled substances. DEA schedules, refill limits, and recordkeeping are the most-tested federal facts — start there.
Use Type and Quiz, not just Flip. Recognizing the right answer is easy; recalling and choosing it is the real test.
Drill your weakest topic. Pick a single topic deck and grind it until the Match time drops and the Quiz score climbs.
Then prove it. When the cards feel easy, confirm with a full practice test — aim comfortably above passing before exam day.

MPJE Flashcards FAQ

Hundreds of free MPJE flashcards, organized across the federal pharmacy law the exam tests — controlled substances, pharmacist practice and dispensing, licensure and personnel, and pharmacy operations. They're free with no account required.

References

1.National Association of Boards of Pharmacy. “Multistate Pharmacy Jurisprudence Examination (MPJE).” nabp.pharmacy. ↑
2.National Association of Boards of Pharmacy. “MPJE Competency Statements.” nabp.pharmacy. ↑
3.U.S. Drug Enforcement Administration. “Drug Scheduling.” dea.gov. ↑

Career Employer

Career Employer is the ultimate resource to help you get started working the job of your dreams. We cover topics from general career information, career searching, exam preparation with free study materials, career interviewing, and becoming successful in your career of choice.

All Posts

Career Employer’s Editorial Process

Here at Career Employer, we focus a lot on providing factually accurate information that is always up to date. We strive to provide correct information using strict editorial processes, article editing, and fact-checking for all of the information found on our website. We only utilize trustworthy and relevant resources. To find out more, make sure to read our full editorial process page here.